Apogee Therapeutics to Present Phase 2 APEX Part B Data as Fund Lifts Stake to $93 Million

Apogee Therapeutics will host a conference call and webcast on May 27, 2026, to present Part B 16-week data from its Phase 2 APEX trial of zumilokibart in moderate-to-severe atopic dermatitis. The planned disclosure is part of the company's staged data-release approach for the APEX program, sequencing clinical evidence to inform the therapy's development pathway.

Apogee Therapeutics is a clinical-stage biotechnology company specializing in the development of extended half-life monoclonal antibodies for the treatment of atopic dermatitis, COPD, and related inflammatory diseases. The company's pipeline includes APG777 for atopic dermatitis and APG808 for chronic obstructive pulmonary disease, with additional candidates targeting inflammatory and immunology indications.

The upcoming APEX Part B 16-week readout sits on top of already encouraging long-term Part A maintenance data and early asthma signals. The company is a pre-revenue company with rising losses and recent equity dilution. As of the latest quarterly report, Apogee reported a net loss of $253.67 million over the trailing twelve months and had a market capitalization of $4 billion.

On February 13, 2026, Affinity Asset Advisors disclosed a purchase of 61,500 shares of Apogee Therapeutics during the fourth quarter of 2025, with an estimated transaction value of $3.87 million based on quarterly average pricing. The fund's quarter-end stake rose to 1,234,926 shares valued at $93.21 million, representing 6.9% of its reportable assets under management. The position value increased by $46.59 million during the period, reflecting both share additions and price appreciation.

As of February 13, 2026, Apogee shares were priced at $67.78, up 86.9% over the past year, with 75.14 percentage points of alpha versus the S&P 500.